IHI's top three holdings—ABT, ISRG, and SYK—comprise nearly 43% of the portfolio, amplifying downside risk if growth falters. Read why IHI ETF is a Sell.
Baxter International has significantly underperformed the broader market over the past year, although analysts remain neutral amid improving fundamentals and recovery prospects.
Boston Scientific underperformed the broader market, though analysts remain optimistic, citing strong earnings execution, innovation, and meaningful upside from current levels.
This is the newest page. Registered accounts read further back.